



UNCOVER THE *BRAF* PATH

Explore the possibilities with targeted treatment

Learn why knowing your *BRAF* mutation status matters—before choosing a treatment for your melanoma.

Get information about **TAFINLAR + MEKINIST**, a targeted treatment that is specifically designed for *BRAF*+ melanoma.

APPROVED USES

TAFINLAR and MEKINIST are prescription medicines that can be used in combination to treat people with a type of skin cancer called melanoma:

- that has spread to other parts of the body (metastatic) or cannot be removed by surgery (unresectable), and
- that has a certain type of abnormal “*BRAF*” (V600E or V600K mutation-positive) gene

TAFINLAR and MEKINIST are prescription medicines that can be used in combination to help prevent melanoma that has a certain type of abnormal “*BRAF*” gene from coming back after the cancer has been removed by surgery.

TAFINLAR, in combination with MEKINIST, is not for use in treating people with wild-type *BRAF* melanoma. MEKINIST should not be used to treat people who already have received a *BRAF* inhibitor for treatment of their melanoma and it did not work or is no longer working.

Your health care provider will perform a test to make sure that TAFINLAR and MEKINIST in combination is right for you.

It is not known if TAFINLAR, in combination with MEKINIST, is safe and effective in children younger than 1 year of age. It is not known if TAFINLAR used alone is safe and effective in children.

Please see additional **Important Safety Information** throughout this brochure and on [pages 16-19](#).

Please see full [Prescribing Information](#) for TAFINLAR, including [Medication Guide](#), and full [Prescribing Information](#) for MEKINIST, including [Patient Information](#).



WHAT TO KNOW ABOUT BRAF



Not an actual patient.

Why do I need to confirm my BRAF mutation status?

Getting the BRAF test confirms the type of melanoma you have, which means that you and your health care provider can be completely informed when choosing your treatment.

BRAF testing is done when your health care provider takes a sample of your melanoma and checks its DNA. If this test shows that your melanoma is BRAF+ (BRAF positive), you have a change in your DNA, also known as a mutation.

Specifically, it means that damage to the BRAF gene is causing cells to grow uncontrollably, leading to cancers such as melanoma. The most common BRAF mutations are called BRAF V600E and BRAF V600K.

Throughout this brochure, BRAF V600E/K melanoma are referred to as BRAF+ melanoma.

IMPORTANT SAFETY INFORMATION

What is the most important information I should know about TAFINLAR in combination with MEKINIST? TAFINLAR and MEKINIST may cause serious side effects, including:

Risk of new skin cancers. TAFINLAR, when used in combination with MEKINIST, may cause a type of skin cancer called cutaneous squamous cell carcinoma, keratoacanthoma, basal cell carcinoma, or melanoma. Talk with your health care provider about your risk for these cancers.

Check your skin and tell your health care provider right away about any skin changes, including a new wart, skin sore, or reddish bump that bleeds or does not heal, or a change in size or color of a mole.

Your health care provider should check your skin before you start treatment, and every 2 months while on treatment, to look for any new skin cancers. Your health care provider should continue to check your skin for 6 months after you stop taking TAFINLAR and MEKINIST.

Please see additional Important Safety Information throughout this brochure and on pages 16-19.

Please see full [Prescribing Information](#) for TAFINLAR, including Medication Guide, and full [Prescribing Information](#) for MEKINIST, including Patient Information.





WHAT IF I HAVE BRAF+ MELANOMA?

Here are some quick facts

- People with BRAF+ melanoma are more likely to have their cancer return after surgery



Nearly 8 of 10 people with BRAF+ melanoma who do not receive any treatment after surgery will see their cancer return.

- People with advanced BRAF+ melanoma may face more serious risks compared with those who are not BRAF+



Not an actual patient.

ABOUT
50%
OF PEOPLE WITH
MELANOMA HAVE A
BRAF MUTATION

If you are one of them, you are not alone.

And you can feel reassured knowing there may be a treatment specifically designed for your type of melanoma.

BRAF+ melanoma can be treated by a targeted therapy— a treatment that finds and targets certain cancer cells with this specific BRAF mutation.

Be ready and empowered.

Knowing your BRAF mutation status matters. **It's important to ask your health care provider to get tested and confirm if you are BRAF+** before mapping out your treatment path.

IMPORTANT SAFETY INFORMATION (continued)

Risk of new skin cancers (continued). Your health care provider should also check for cancers that may not occur on the skin. Tell your health care provider about any new symptoms that have developed while taking TAFINLAR and MEKINIST in combination.

Please see additional Important Safety Information throughout this brochure and on pages 16-19.

Please see full [Prescribing Information](#) for TAFINLAR, including Medication Guide, and full [Prescribing Information](#) for MEKINIST, including Patient Information.






WHAT IS TAFINLAR + MEKINIST?

TAFINLAR + MEKINIST is a combination therapy for BRAF+ melanoma. It is a targeted therapy that can be used to treat 2 different stages of BRAF+ melanoma*:

- **Adjuvant** (after surgical removal) treatment of BRAF+ melanoma, to help prevent your melanoma from coming back after surgery
- Treatment of **metastatic** (has spread to other parts of the body) melanoma or **unresectable** (cannot be removed by surgery) melanoma

HOW DOES IT WORK?

Certain melanoma cancer cells with the BRAF mutation can grow uncontrollably.



TAFINLAR + MEKINIST may help slow the growth of certain melanoma cancer cells with the BRAF mutation.

TAFINLAR and MEKINIST work together, with each targeting a different point in the cell-signaling process. Although TAFINLAR + MEKINIST targets specific cancer cells, it can also affect healthy cells in the body.

*TAFINLAR + MEKINIST should not be used to treat people with a type of skin cancer called wild-type BRAF melanoma. MEKINIST should not be used to treat people who already have received a BRAF inhibitor for treatment of their melanoma and it did not work or is no longer working. In clinical studies, patients with BRAF+ melanoma had either the V600E or V600K mutation.

IMPORTANT SAFETY INFORMATION (continued)

Bleeding problems. TAFINLAR and MEKINIST in combination can cause serious bleeding problems, especially in your brain or stomach, that can lead to death. Call your health care provider and get medical help right away if you have any signs of bleeding, including:

- headaches, dizziness, or feeling weak
- vomiting blood or your vomit looks like “coffee grounds”
- coughing up blood or blood clots
- red or black stools that look like tar

Please see additional Important Safety Information throughout this brochure and on pages 16-19.

Please see full [Prescribing Information](#) for TAFINLAR, including [Medication Guide](#), and full [Prescribing Information](#) for MEKINIST, including [Patient Information](#).





WHAT OTHER INFORMATION SHOULD I KNOW ABOUT TAFINLAR + MEKINIST?



TAFINLAR + MEKINIST is **not a chemotherapy**.




Because TAFINLAR + MEKINIST is **an oral therapy**, you will not need to travel to an infusion center to receive your treatment.



Novartis offers **support and helpful resources** for patients taking TAFINLAR + MEKINIST and their caregivers.



TAFINLAR + MEKINIST is **the most prescribed combination targeted therapy** for patients with **BRAF+ melanoma** worldwide, as of December 2021.



Visit www.us.TafinlarMekinist.com to learn more about the benefits of TAFINLAR + MEKINIST.

IMPORTANT SAFETY INFORMATION (continued)

Inflammation of the intestines or tears (perforation) of the stomach or intestines. MEKINIST, alone or in combination with TAFINLAR, can cause inflammation of your intestines, or tears in the stomach or intestines that can lead to death. Tell your health care provider right away if you have any of the following symptoms:

- bleeding (see “Bleeding problems”)
- diarrhea (loose stools) or more bowel movements than usual
- stomach-area (abdomen) pain or tenderness
- fever
- nausea

Please see additional Important Safety Information throughout this brochure and on pages 16-19.

Please see full [Prescribing Information](#) for TAFINLAR, including [Medication Guide](#), and full [Prescribing Information](#) for MEKINIST, including [Patient Information](#).





TAFINLAR + MEKINIST FOR AFTER SURGERY...

TAFINLAR + MEKINIST was studied in patients with stage III BRAF+ melanoma previously removed by surgery. Eight hundred seventy adult patients were treated with a combination of TAFINLAR + MEKINIST or placebo for 12 months.

At first check-in with a median follow-up of 34 months:

After 1 year of treatment, TAFINLAR + MEKINIST

reduced the risk of cancer returning after surgery by approximately 53%

(vs placebo)



53%



Your health care provider may prescribe TAFINLAR + MEKINIST to help prevent your BRAF+ melanoma from coming back after it has been removed by surgery.

IMPORTANT SAFETY INFORMATION (continued)

Blood clots. TAFINLAR and MEKINIST in combination can cause blood clots in your arms or legs, which can travel to your lungs and lead to death. Get medical help right away if you have the following symptoms:

- chest pain
- sudden shortness of breath or trouble breathing
- pain in your legs with or without swelling
- swelling in your arms or legs
- a cool, pale arm or leg

Please see additional Important Safety Information throughout this brochure and on pages 16-19.

Please see full [Prescribing Information](#) for TAFINLAR, including Medication Guide, and full [Prescribing Information](#) for MEKINIST, including Patient Information.





LOWERED THE CHANCE OF CANCER RETURNING


WITH TAFINLAR + MEKINIST,
**52% of patients were cancer
free and treatment free at**

5
YEARS

(vs 36% with placebo)

- This analysis was not pre-planned to detect a false positive or show a difference between treatments

Not an actual patient.



Learn more about TAFINLAR + MEKINIST for after surgery.
Visit www.us.TafinlarMekinist.com.

IMPORTANT SAFETY INFORMATION (continued)

Heart problems, including heart failure. Your health care provider should check your heart function before you start taking TAFINLAR and MEKINIST in combination, and during treatment. Call your health care provider right away if you have any of the following signs and symptoms of a heart problem:


- feeling like your heart is pounding or racing
- shortness of breath
- swelling of your ankles and feet
- feeling lightheaded

Please see additional Important Safety Information throughout this brochure and on pages 16-19.

Please see full [Prescribing Information](#) for TAFINLAR, including Medication Guide, and full [Prescribing Information](#) for MEKINIST, including Patient Information.


Tafinlar[®]
(dabrafenib)
50 mg, 75 mg capsules


Mekinist[®]
(trametinib)
0.5 mg, 2 mg tablets



TAFINLAR + MEKINIST FOR ADVANCED MELANOMA...

TAFINLAR + MEKINIST was studied in patients with advanced (unresectable or metastatic) BRAF+ melanoma.

Seven hundred four adult patients were treated with a combination of TAFINLAR + MEKINIST or vemurafenib (another cancer drug) alone.

WITH TAFINLAR + MEKINIST, 36% of patients were still alive at

(vs 23% of patients receiving vemurafenib)



- At first check-in, TAFINLAR + MEKINIST reduced the risk of death by 31% vs vemurafenib
- This analysis was not pre-planned to detect a false positive or show a difference between treatments

Not an actual patient.

IMPORTANT SAFETY INFORMATION (continued)

Eye problems. TAFINLAR and MEKINIST, in combination, can cause severe eye problems that can lead to blindness. Call your health care provider right away if you get these symptoms of eye problems:

- blurred vision, loss of vision, or other vision changes
- seeing color dots
- halo (seeing blurred outline around objects)
- eye pain, swelling, or redness

Please see additional Important Safety Information throughout this brochure and on pages 16-19.

Please see full [Prescribing Information](#) for TAFINLAR, including [Medication Guide](#), and full [Prescribing Information](#) for MEKINIST, including [Patient Information](#).






MAY OFFER A CHANCE TO EXTEND YOUR LIFE

TAFINLAR + MEKINIST was studied in 121 adult patients with BRAF V600E/K mutation–positive melanoma that had spread to the brain. Patients were treated with TAFINLAR + MEKINIST.



In TAFINLAR + MEKINIST patients who had their melanoma spread to the brain:

50% had their brain tumors shrink or disappear.



Learn more about TAFINLAR + MEKINIST for advanced melanoma. Visit www.us.TafinlarMekinist.com.

IMPORTANT SAFETY INFORMATION (continued)

Lung or breathing problems. TAFINLAR and MEKINIST, in combination, can cause lung or breathing problems. Tell your health care provider if you have any new or worsening symptoms of lung or breathing problems, including:

- shortness of breath
- cough

Fever. Fever is common during treatment with TAFINLAR and MEKINIST, but it may also be serious. When taking TAFINLAR and MEKINIST, in combination, fever may happen often or may be severe. In some cases, chills or shaking chills, too much fluid loss (dehydration), low blood pressure, dizziness, or kidney problems may happen with the fever. Call your health care provider right away if you get a fever while taking TAFINLAR or MEKINIST.

Your health care provider may temporarily or permanently stop your treatment or change your dose of MEKINIST with TAFINLAR if you have fevers. Your health care provider will treat you as needed for your fever and any signs and symptoms of infection and should check your kidney function during and after you have had severe fever.

Please see additional Important Safety Information throughout this brochure and on pages 16–19.

Please see full [Prescribing Information](#) for TAFINLAR, including [Medication Guide](#), and full [Prescribing Information](#) for MEKINIST, including [Patient Information](#).





HOW DO I TAKE TAFINLAR + MEKINIST?

Because it is a combination treatment of 2 different medications with different strengths, it's very important to understand how to take TAFINLAR + MEKINIST the right way.

The recommended dosage of TAFINLAR + MEKINIST is 2 capsules of TAFINLAR (the dark pink capsule) twice a day (4 capsules each day) + 1 tablet of MEKINIST (the light pink circular tablet) once a day (1 tablet each day).

It's recommended that you take the TAFINLAR doses about 12 hours apart.

Since TAFINLAR + MEKINIST is an oral treatment, you'll take it by mouth—at least 1 hour before or at least 2 hours after eating.

Do not open, crush, or break TAFINLAR capsules.



First Dose: Morning



TAFINLAR 150 mg (2 x 75 mg)

12-HOUR INTERVAL BETWEEN TAFINLAR DOSES



Second Dose: Evening



TAFINLAR 150 mg (2 x 75 mg)

AND



Once Daily



MEKINIST 2 mg (1 x 2 mg)

Take **MEKINIST** at the same time each day with either the morning dose or evening dose of **TAFINLAR**

Capsules and tablet shown are not actual size or likeness.

IMPORTANT SAFETY INFORMATION (continued)

Serious skin reactions. Skin rash is a common side effect of TAFINLAR and MEKINIST. In some cases, these rashes and other skin reactions can be severe or serious, may need to be treated in a hospital, or lead to death.

Please see additional Important Safety Information throughout this brochure and on pages 16-19.

Please see full [Prescribing Information](#) for TAFINLAR, including Medication Guide, and full [Prescribing Information](#) for MEKINIST, including Patient Information.





WHAT HAPPENS IF I MISS A DOSE?

If you miss a dose of TAFINLAR and/or MEKINIST—don't panic, it happens. **Take it as soon as you remember, unless:**

- You've missed TAFINLAR and it is within 6 hours of your next scheduled dose, or
- You've missed MEKINIST and it is within 12 hours of your next scheduled dose

In either case, just take your next dose at the regular time. Do not make up for the missed dose.

It is important that you understand and follow your health care provider's directions for taking TAFINLAR + MEKINIST. Do not change your dose or stop taking TAFINLAR or MEKINIST unless your health care provider tells you to do so.

How to store TAFINLAR + MEKINIST

Storing TAFINLAR

- Store TAFINLAR at room temperature, between 68 °F and 77 °F
- Keep TAFINLAR and the drying agent (desiccant) in the original bottle to protect from moisture

Storing MEKINIST

- Store MEKINIST in the refrigerator between 36 °F and 46 °F
- Keep MEKINIST dry and away from moisture and light
- The bottle of MEKINIST contains a packet that helps keep your medicine dry. Do not throw away this packet
- Keep MEKINIST in the original bottle. Do not place tablets in a pill box
- Safely throw away MEKINIST that is expired or no longer needed



TIP: Develop a routine for taking your medicine that fits your daily schedule. For example, you can take TAFINLAR + MEKINIST in the morning, an hour before breakfast, and then take TAFINLAR again in the evening, 2 hours after dinner.

IMPORTANT SAFETY INFORMATION (continued)

Serious skin reactions (continued).

- tell your health care provider if you get a skin rash or acne that bothers you or worsens
- **tell your health care provider right away if you develop any of the following signs or symptoms of a severe skin reaction, including:**
 - blisters or peeling of your skin
 - mouth sores
 - high fever or flu-like symptoms
 - blisters on your lips, or around your mouth or eyes
 - enlarged lymph nodes

Please see additional Important Safety Information throughout this brochure and on pages 16-19.

Please see full [Prescribing Information](#) for TAFINLAR, including Medication Guide, and full [Prescribing Information](#) for MEKINIST, including Patient Information.






UNCOVER ADDITIONAL SUPPORT DESIGNED FOR YOU

Patient Support Resources by Insurance Type

Resource	Commercial	Government	Uninsured
Universal Co-pay Card	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>
Patient Assistance Now Oncology (PANO)	<input checked="" type="checkbox"/>	<input checked="" type="checkbox"/>	<input checked="" type="checkbox"/>
30-Day Free Trial	<input checked="" type="checkbox"/>	<input checked="" type="checkbox"/>	<input checked="" type="checkbox"/>
Voucher Program	<input checked="" type="checkbox"/>	<input checked="" type="checkbox"/>	<input checked="" type="checkbox"/>

Additional Resources	Commercial	Government	Uninsured
In-Office Samples	<input checked="" type="checkbox"/>	<input checked="" type="checkbox"/>	<input checked="" type="checkbox"/>
Novartis Patient Assistance Foundation (NPAF)	<input checked="" type="checkbox"/>	<input checked="" type="checkbox"/>	<input checked="" type="checkbox"/>



For more available resources and support materials, please visit www.us.TafinlarMekinist.com.

Please see additional Important Safety Information throughout this brochure and on pages 16-19.

Please see full [Prescribing Information](#) for TAFINLAR, including Medication Guide, and full [Prescribing Information](#) for MEKINIST, including Patient Information.





Novartis Oncology Universal Co-pay Program

You may be eligible for immediate co-pay savings on your next prescription of TAFINLAR + MEKINIST.



Universal Co-pay Card
Save on your out-of-pocket costs

To find out if you are eligible, call **1-877-577-7756**, or visit Copay.NovartisOncology.com

- Eligible patients with private insurance may pay \$0 per month (\$0 per month for a 30-day supply of TAFINLAR and \$0 for a 30-day supply of MEKINIST). Co-pay of \$0 is only for TAFINLAR + MEKINIST combination therapy
- Novartis will pay the remaining co-pay, up to \$15,000 per calendar year, per product*



To find out if you are eligible for the Universal Co-pay Program, call **1-877-577-7756** or visit [CoPay.NovartisOncology.com](http://Copay.NovartisOncology.com).

*Limitations apply. This offer is only available to patients with private insurance. The program is not available for patients who are enrolled in Medicare, Medicaid, or any other federal or state health care program. Novartis reserves the right to rescind, revoke, or amend this program without notice. For full Terms and Conditions, visit Copay.NovartisOncology.com or call 1-877-577-7756.


Patient Assistance Now Oncology

Our Patient Assistance Now Oncology (PANO) program was created to assist you with accessing your Novartis medicine(s)—from insurance verification to financial assistance—all through a knowledgeable and supportive call center.



Patient Assistance Now Oncology

Assistance. Access. Answers.



To learn more, call **1-800-282-7630** or visit Patient.NovartisOncology.com.

Free Trial and Access Program

With the Free Trial and Access Program, you can receive a free supply of TAFINLAR + MEKINIST for a US Food and Drug Administration–approved indication. The supply can be shipped directly to your home or another convenient location so you can start treatment immediately. Program rules may vary by product.



Ask your health care professional to help you apply for the PANO Free Trial and Access Program.

Please see additional **Important Safety Information** throughout this brochure and on pages 16–19.

Please see full [Prescribing Information](#) for TAFINLAR, including [Medication Guide](#), and full [Prescribing Information](#) for MEKINIST, including [Patient Information](#).





WE'RE ALL IN THIS TOGETHER

Community and support are critical to helping you take on **BRAF+** melanoma. The following organizations may provide additional information, connections, and support for you and your loved ones during your TAFINLAR + MEKINIST treatment journey. Several of these websites offer forums where you can connect with other patients and caregivers.

Connecting with advocacy groups can help you build a community with others who understand what you're experiencing.

AIM at Melanoma Foundation
aimatmelanoma.org

Melanoma Research Foundation
melanoma.org

Caregiver Action Network
caregiveraction.org

Cancer Support Community
cancersupportcommunity.org

The organizations and websites listed above are external to Novartis. Novartis does not have control over the information provided on these websites and, therefore, cannot guarantee their accuracy and completeness. Any information you receive from these sites should not replace the medical advice from your health care provider.



TAFINLAR + MEKINIST on Facebook and Instagram

Find tips for treatment and managing side effects, and hear stories from fellow patients and supporters. **To stay connected.**



Like the TAFINLAR + MEKINIST page on [Facebook](#).



Follow the TAFINLAR + MEKINIST page on [Instagram](#).

Please see additional Important Safety Information throughout this brochure and on pages 16-19.

Please see full [Prescribing Information](#) for TAFINLAR, including Medication Guide, and full [Prescribing Information](#) for MEKINIST, including Patient Information.





Not actual patients.

Caregivers need care, too.

As a caregiver of someone diagnosed with *BRAF+* melanoma, your responsibilities may seem overwhelming. It is important to help your loved one without forgetting about your own needs. You can take steps to plan ahead and learn more about the disease, which can help you cope and adjust to the changes in your life and the life of your loved one.

Remember, you are best able to support your loved one when you're taking care of yourself.

Sometimes that means taking a break, whether that means ordering takeout instead of cooking, keeping up with your hobbies, or seeing friends.

IMPORTANT SAFETY INFORMATION (continued)

Increased blood sugar (hyperglycemia). Some people may develop high blood sugar or worsening diabetes during treatment with TAFINLAR and MEKINIST in combination. If you are diabetic, your health care provider should check your blood sugar levels closely during treatment with TAFINLAR and MEKINIST. Your diabetes medicine may need to be changed. Tell your health care provider if you have any of the following symptoms of severe high blood sugar:

- increased thirst
- urinating more often than normal, or urinating an increased amount of urine

Please see additional Important Safety Information throughout this brochure and on pages 16-19.

Please see full [Prescribing Information](#) for TAFINLAR, including Medication Guide, and full [Prescribing Information](#) for MEKINIST, including Patient Information.





APPROVED USES

TAFINLAR and MEKINIST are prescription medicines that can be used in combination to treat people with a type of skin cancer called melanoma:

- that has spread to other parts of the body (metastatic) or cannot be removed by surgery (unresectable), and
- that has a certain type of abnormal “BRAF” (V600E or V600K mutation-positive) gene

TAFINLAR and MEKINIST are prescription medicines that can be used in combination to help prevent melanoma that has a certain type of abnormal “BRAF” gene from coming back after the cancer has been removed by surgery.

TAFINLAR, in combination with MEKINIST, is not for use in treating people with wild-type BRAF melanoma. MEKINIST should not be used to treat people who already have received a BRAF inhibitor for treatment of their melanoma and it did not work or is no longer working.

Your health care provider will perform a test to make sure that TAFINLAR and MEKINIST in combination is right for you.

It is not known if TAFINLAR, in combination with MEKINIST, is safe and effective in children younger than 1 year of age. It is not known if TAFINLAR used alone is safe and effective in children.

IMPORTANT SAFETY INFORMATION

What is the most important information I should know about TAFINLAR in combination with MEKINIST? TAFINLAR and MEKINIST may cause serious side effects, including:

Risk of new skin cancers. TAFINLAR, when used in combination with MEKINIST, may cause a type of skin cancer called cutaneous squamous cell carcinoma, keratoacanthoma, basal cell carcinoma, or melanoma. Talk with your health care provider about your risk for these cancers.

Please see additional Important Safety Information throughout this brochure and on pages 16-19.

Please see full [Prescribing Information](#) for TAFINLAR, including [Medication Guide](#), and full [Prescribing Information](#) for MEKINIST, including [Patient Information](#).

Check your skin and tell your health care provider right away about any skin changes, including a new wart, skin sore, or reddish bump that bleeds or does not heal, or a change in size or color of a mole.

Your health care provider should check your skin before you start treatment, and every 2 months while on treatment, to look for any new skin cancers. Your health care provider should continue to check your skin for 6 months after you stop taking TAFINLAR and MEKINIST.

Your health care provider should also check for cancers that may not occur on the skin. Tell your health care provider about any new symptoms that have developed while taking TAFINLAR and MEKINIST in combination.

Bleeding problems. TAFINLAR and MEKINIST in combination can cause serious bleeding problems, especially in your brain or stomach, that can lead to death. Call your health care provider and get medical help right away if you have any signs of bleeding, including:

- headaches, dizziness, or feeling weak
- coughing up blood or blood clots
- vomiting blood or your vomit looks like “coffee grounds”
- red or black stools that look like tar

Inflammation of the intestines or tears (perforation) of the stomach or intestines. MEKINIST, alone or in combination with TAFINLAR, can cause inflammation of your intestines, or tears in the stomach or intestines that can lead to death. Tell your health care provider right away if you have any of the following symptoms:

- bleeding (see “Bleeding problems”)
- diarrhea (loose stools) or more bowel movements than usual
- stomach-area (abdomen) pain or tenderness
- fever
- nausea



50 mg, 75 mg capsules

0.5 mg, 2 mg tablets



IMPORTANT SAFETY INFORMATION (continued)

Blood clots. TAFINLAR and MEKINIST in combination can cause blood clots in your arms or legs, which can travel to your lungs and lead to death. Get medical help right away if you have the following symptoms:

- chest pain
- sudden shortness of breath or trouble breathing
- pain in your legs with or without swelling
- swelling in your arms or legs
- a cool, pale arm or leg

Heart problems, including heart failure. Your health care provider should check your heart function before you start taking TAFINLAR and MEKINIST in combination, and during treatment. Call your health care provider right away if you have any of the following signs and symptoms of a heart problem:

- feeling like your heart is pounding or racing
- shortness of breath
- swelling of your ankles and feet
- feeling lightheaded

Eye problems. TAFINLAR and MEKINIST, in combination, can cause severe eye problems that can lead to blindness. Call your health care provider right away if you get these symptoms of eye problems:

- blurred vision, loss of vision, or other vision changes
- seeing color dots
- halo (seeing blurred outline around objects)
- eye pain, swelling, or redness

Lung or breathing problems. TAFINLAR and MEKINIST, in combination, can cause lung or breathing problems. Tell your health care provider if you have any new or worsening symptoms of lung or breathing problems, including:

- shortness of breath
- cough

Fever. Fever is common during treatment with TAFINLAR and MEKINIST, but it may also be serious. When taking TAFINLAR and MEKINIST, in combination, fever may happen often or may be severe. In some cases, chills or shaking chills, too much fluid loss (dehydration), low blood pressure, dizziness, or kidney problems may happen with the fever. Call your health care provider right away if you get a fever while taking TAFINLAR or MEKINIST.

Your health care provider may temporarily or permanently stop your treatment or change your dose of MEKINIST with TAFINLAR if you have fevers. Your health care provider will treat you as needed for your fever and any signs and symptoms of infection and should check your kidney function during and after you have had severe fever.

Serious skin reactions. Skin rash is a common side effect of TAFINLAR and MEKINIST. In some cases, these rashes and other skin reactions can be severe or serious, may need to be treated in a hospital, or lead to death.

- tell your health care provider if you get a skin rash or acne that bothers you or worsens
- **tell your health care provider right away if you develop any of the following signs or symptoms of a severe skin reaction, including:**
 - blisters or peeling of your skin
 - mouth sores
 - high fever or flu-like symptoms
 - blisters on your lips, or around your mouth or eyes
 - enlarged lymph nodes

Please see additional Important Safety Information throughout this brochure and on pages 16-19.

Please see full [Prescribing Information](#) for TAFINLAR, including [Medication Guide](#), and full [Prescribing Information](#) for MEKINIST, including [Patient Information](#).



What to know about BRAF	What is TAFINLAR + MEKINIST?	TAFINLAR + MEKINIST for after surgery	TAFINLAR + MEKINIST for advanced melanoma	Dosing	Patient Support	Important Safety Information
-------------------------	------------------------------	---------------------------------------	---	--------	-----------------	------------------------------



IMPORTANT SAFETY INFORMATION (continued)

Increased blood sugar (hyperglycemia). Some people may develop high blood sugar or worsening diabetes during treatment with TAFINLAR and MEKINIST in combination. If you are diabetic, your health care provider should check your blood sugar levels closely during treatment with TAFINLAR and MEKINIST. Your diabetes medicine may need to be changed. Tell your health care provider if you have any of the following symptoms of severe high blood sugar:

- increased thirst
- urinating more often than normal, or urinating an increased amount of urine

TAFINLAR may cause healthy red blood cells to break down too early in people with glucose-6-phosphate dehydrogenase (G6PD) deficiency. This may lead to a type of anemia called hemolytic anemia, where the body does not have enough healthy red blood cells. Tell your health care provider if you have any of the following signs or symptoms:

- yellow skin (jaundice)
- weakness or dizziness
- shortness of breath

Hemophagocytic Lymphohistiocytosis (HLH).

TAFINLAR when taken with MEKINIST may increase the risk of a type of overactivity of the immune system (hemophagocytic lymphohistiocytosis) that can cause fever, swollen glands, bruising, or skin rash. If you experience a combination of these symptoms, call your health care provider right away.

TAFINLAR and MEKINIST, in combination, can harm your unborn baby.

Your health care provider will do a test to see if you are pregnant before starting treatment with TAFINLAR and MEKINIST in combination.

Women who are able to become pregnant should use effective birth control (contraception) during treatment with TAFINLAR and MEKINIST

in combination, and for 4 months after stopping treatment with TAFINLAR and MEKINIST.

Birth control using hormones (such as birth control pills, injections, or transdermal systems) may not work as well while you are taking TAFINLAR and MEKINIST in combination. You should use another effective method of birth control while taking TAFINLAR and MEKINIST in combination.

Talk to your health care provider about birth control methods that may be right for you during this time.

Tell your health care provider right away if you become pregnant, or think you might be pregnant, during treatment with TAFINLAR and MEKINIST in combination.

Men (including those who have had a vasectomy) with a female partner who is able to become pregnant should use condoms during sexual intercourse during treatment with TAFINLAR and MEKINIST for at least 4 months after your last dose of TAFINLAR and MEKINIST in combination.

The most common side effects of TAFINLAR, in combination with MEKINIST, when used in patients with melanoma that has spread to other parts of the body or cannot be removed by surgery include:

- fever
- rash
- nausea
- headache
- chills
- diarrhea
- vomiting
- high blood pressure (hypertension)
- joint aches
- swelling of the face, arms, or legs
- cough

Please see additional Important Safety Information throughout this brochure and on pages 16-19.

Please see full [Prescribing Information](#) for TAFINLAR, including [Medication Guide](#), and full [Prescribing Information](#) for MEKINIST, including [Patient Information](#).





IMPORTANT SAFETY INFORMATION (continued)

The most common side effects of TAFINLAR, in combination with MEKINIST, when used in patients to help prevent melanoma from coming back after the cancer has been removed by surgery include:

- fever
- tiredness
- nausea
- headache
- rash
- chills
- diarrhea
- vomiting
- joint aches
- muscle aches

New or worsening high blood pressure (hypertension).

Your health care provider should check your blood pressure during treatment with MEKINIST. Call your health care provider right away if you develop high blood pressure, your blood pressure worsens, or you have severe headache, lightheadedness, blurry vision, or dizziness.

Fertility problems. TAFINLAR and MEKINIST, in combination, may cause fertility problems in women. This could affect the ability to become pregnant. Talk to your health care provider if this is a concern for you.

Low sperm counts. TAFINLAR may cause lower sperm counts in men. This could affect the ability to father a child. Talk to your health care provider if this is a concern for you.

Nursing mothers. It is not known if TAFINLAR and/or MEKINIST pass into breast milk. Do not breastfeed during treatment, and for 4 months after your last dose of TAFINLAR and MEKINIST. Talk to your health care provider about the best way to feed your baby during this time.

These are not all the possible side effects of TAFINLAR and MEKINIST. For more information about side effects, ask your health care provider or pharmacist.

Before you take TAFINLAR and MEKINIST in combination, tell your health care provider about all your medical conditions, including if you:

- have had bleeding problems or blood clots
- have stomach problems
- have inflammation of the colon
- have heart problems
- have eye problems
- have lung or breathing problems
- have high blood pressure (hypertension)
- have liver or kidney problems
- have diabetes
- plan to have surgery, dental, or other medical procedures
- have a deficiency of the G6PD enzyme
- are pregnant or plan to become pregnant
- are breastfeeding or plan to breastfeed

Tell your health care provider about all the medicines you take, including prescription and over-the-counter medicines, vitamins, and herbal supplements. Know the medicines you take. Keep a list of them to show your health care provider and pharmacist when you get a new medicine.

Please read the Medication Guide for TAFINLAR and the Patient Information for MEKINIST and discuss any questions you have with your health care provider.

You are encouraged to report negative side effects of prescription drugs to the FDA. Visit www.fda.gov/medwatch, or call [1-800-FDA-1088](tel:1-800-FDA-1088).

Please see additional Important Safety Information throughout this brochure and on pages 16-19.

Please see full [Prescribing Information](#) for TAFINLAR, including [Medication Guide](#), and full [Prescribing Information](#) for MEKINIST, including [Patient Information](#).





TALK TO YOUR HEALTH CARE PROVIDER

Now that you've learned about the importance of *BRAF* testing and about how TAFINLAR + MEKINIST may help you, **your next step is to have an open and honest conversation with your health care provider.**

Here are some conversation starters for your next appointment:


- What should I know about my *BRAF* mutation status and what does it mean for my melanoma?
- How can I get tested for *BRAF* mutation status before deciding on my melanoma treatment?
- What can you tell me about TAFINLAR + MEKINIST?
- Is TAFINLAR + MEKINIST right for me?

Not actual patients.




Be ready to advocate for your health.

Ask your health care provider about *BRAF* mutation testing.



Visit www.us.TafinlarMekinist.com to learn more about the No. 1 prescribed targeted therapy for *BRAF*+ melanoma worldwide.



For more available resources and support materials, please visit www.us.TafinlarMekinist.com.

IMPORTANT SAFETY INFORMATION (continued)

Fever. Fever is common during treatment with TAFINLAR and MEKINIST, but it may also be serious. When taking TAFINLAR and MEKINIST, in combination, fever may happen often or may be severe. In some cases, chills or shaking chills, too much fluid loss (dehydration), low blood pressure, dizziness, or kidney problems may happen with the fever. Call your health care provider right away if you get a fever while taking TAFINLAR or MEKINIST.

Please see additional Important Safety Information throughout this brochure and on [pages 16-19](#).

Please see full [Prescribing Information](#) for TAFINLAR, including Medication Guide, and full [Prescribing Information](#) for MEKINIST, including Patient Information.

